ORPHA:1807
Focal facial dermal dysplasia type III
Also known as: FFDD type III · FFDD3 · Focal facial dermal dysplasia 3, Setleis type · Setleis syndrome
Query health: suspect — Only one of 2 strategies returned hits (phrase).
Publications
86
48.5th percentile
Trials
0
Interventional, condition-specific
Researchers
507
Distinct authors in sample
Gene link
TWIST2
Strong
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
Focal facial dermal type III (FFDD3) is a rare focal facial dermal (FFDD), characterized primarily by bitemporal scar-like depressions and a typical, but variable facial dysmorphism, which may include distichiasis (upper lids) or lacking eyelashes, slanted eyebrows and a flattened and/or bulbous nasal tip and other features such as a low frontal hairline, sparse hair, redundant skin, epicanthal folds, low-set dysplastic ears, blepharitis and conjunctivitis.
How rare: How common this is has not been clearly measured.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0009203
- OMIM:227260
- UMLS:C1744559
Additional Mondo synonyms (2)
focal facial dermal dysplasia 3, Setleis type · focal facial dermal dysplasia type III
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
No matched interventional trial; the gene is known and literature exists — preclinical or natural-history work may still be the practical next step.
- Gene identifiedPresent
Strong — TWIST2
- LiteraturePresent
86 matched papers (38 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialNot found
No matched interventional trial under our ClinicalTrials.gov rules
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Yes — we know a specific gene responsible (TWIST2).
GenCC classification: Strong.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
86
86 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
86 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
38 in the last 10 years · high confidence · 48.5th percentile (publications denominator)
Phrase hits: 86 · MeSH hits: 0
Who's working on it?
507
Distinct author names in 86 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Desnick RJ10 papers · 2021
Department of Genetics and Genomic Sciences, Mount Sinai School of Medicine, New York, New York.
Papers in Europe PMC - 02Cadilla CL7 papers · 2023
Department of Biochemistry, School of Medicine, University of Puerto Rico, San Juan, Puerto Rico, United States of America.
Papers in Europe PMC - 03Edelmann L4 papers · 2017
Department of Genetics and Genomic Sciences, Mount Sinai School of Medicine, New York, New York.
Papers in Europe PMC - 04Franco HL4 papers · 2023
Human Molecular Genetics Lab, Department of Biochemistry, School of Medicine University of Puerto Rico, Medical Sciences Campus, PO Box 365067, San Juan, PR 00936, USA.
Papers in Europe PMC - 05Lee BH4 papers · 2017
Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, USA.
Papers in Europe PMC - 06Nazarenko I4 papers · 2015
Department of Genetics and Genomic Sciences, Mount Sinai School of Medicine, New York, New York.
Papers in Europe PMC - 07Zhang S4 papers · 2023
Department of Plastic and Reconstructive Surgery, Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Papers in Europe PMC - 08Al-Gazali LI2 papers · 2010
Department of Paediatrics, Faculty of Medicine and Health Sciences, UAE University, Al Ain, UAE.
Papers in Europe PMC - 09Atit RP2 papers · 2018
Department of Biology, Case Western Reserve University, Cleveland, Ohio.
Papers in Europe PMC - 10Cao Q2 papers · 2022
Department of Pathology and Pathophysiology, Zhejiang University School of Medicine, Hangzhou 310058, China.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present).
Data as of 27 July 2026
No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.
high confidence · 36.5th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
Broader category focal facial dermal dysplasia also has no matched interventional trial. See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.
Broader category: focal facial dermal dysplasia
0
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Parent-category matching found a broader label but no interventional trials under it. How we count trials.
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Focal facial dermal dysplasia type III" OR "FFDD type III" OR "FFDD3" OR "Focal facial dermal dysplasia 3, Setleis type" OR "Setleis syndrome"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Focal facial dermal dysplasia type III" OR "FFDD type III" OR "FFDD3" OR "Focal facial dermal dysplasia 3, Setleis type" OR "Setleis syndrome" OR "TWIST2" OR "ectodermal dysplasia syndrome"
Recall-expansion terms: TWIST2, ectodermal dysplasia syndrome
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"focal facial dermal dysplasia"
Query health: suspect — strategies attempted: phrase, recall-expansion; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-26T18:12:15.779Z